



October 16, 2014

Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year

TARRYTOWN, N.Y., Oct. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: **REGN**) today announced it has been recognized by *Science Magazine* as the number one employer in the global biopharmaceutical industry for the third consecutive year, according to the journal's annual Top Employers Survey.

"Regeneron's success can be directly attributed to our incredible, dedicated employees who have an unparalleled commitment to turning science into medicines that will help people with serious diseases," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "Our unique culture nurtures and rewards innovation in R&D and throughout the company."

The award indicates that Regeneron earned high marks among survey respondents for being an innovative leader in industry, treating employees with respect, engendering employee loyalty, operating in a manner that is socially responsible, having clear vision and producing important, quality research.

"As our company grows, we remain relentless in our focus on advancing cutting-edge scientific innovation and achievement," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "Every one of our nearly 3,000 employees knows that he or she has an important impact on advancing meaningful work that will help patients."

The 2014 *Science* survey sought to identify the companies with the best reputations as employers, based on 5,394 survey responses from readers of *Science* and other survey invitees. Survey participants came from North America (70%), Europe (23%), and Asia/Pacific Rim (6%); ninety-one percent work in biotechnology, biopharmaceutical, and pharmaceutical companies.

For the complete feature along with individual company rankings, please visit www.sciencecareers.org/TopEmployers2014.

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. Several Regeneron programs are based on human genetics findings. For additional information about the company, please visit www.regeneron.com.

Forward-Looking Statements

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned; unforeseen safety issues resulting from the administration of products and product candidates in patients; serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products; ongoing regulatory obligations and oversight impacting Regeneron's products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto. A more

complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2013 and its Form 10-Q for the quarter ended June 30, 2014. The reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Your Investor Relations Contact at Regeneron:

Manisha Narasimhan, Ph.D. Tel. 914.847.5126

E-Mail: manisha.narasimhan@regeneron.com

Your Media Contact at Regeneron:

Alexandra Bowie, Tel. 914.847.3407

E-Mail: alexandra.bowie@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media